Application 020520

Type
NDA
Sponsor
SANOFI US

Application Products#

Product, Drug, Ingredient table
ProductDrugIngredientFormStrengthReference drugReference standard
001ZANTAC 75RANITIDINE HYDROCHLORIDETABLET;ORALEQ 75MG BASEYesNo

NDC Listings For This Application#

NDC, Name, Nonproprietary name table
NDCNameNonproprietary nameLabelerMarketing categoryStatus
0597-0122Zantac 75ranitidineBoehringer Ingelheim Pharmaceuticals Inc.NDACurrent
0597-0122Zantac 75ranitidineBoehringer Ingelheim Pharmaceuticals Inc.NDACurrent
41167-0300Zantac 75Ranitidine HydrochlorideChattem, Inc.NDACurrent
41167-0300Zantac 75Ranitidine HydrochlorideChattem, Inc.NDACurrent
50269-222Zantac 75RANITIDINEJC World Bell Wholesale Co., Inc.NDACurrent
50269-222Zantac 75RANITIDINEJC World Bell Wholesale Co., Inc.NDACurrent
67751-152Zantac 75RANITIDINENavajo Manufacturing Company Inc.NDACurrent
67751-152Zantac 75RANITIDINENavajo Manufacturing Company Inc.NDACurrent
68151-2584Zantac 75ranitidineCarilion Materials ManagementNDACurrent
76413-317ZantacranitidineCentral Texas Community Health CentersNDACurrent

Documents#

Document, Submission type, Date table
DocumentSubmission typeDate
60052SUPPL2019-09-19
60046SUPPL2019-09-19
58239SUPPL2019-04-08
58238SUPPL2019-04-08
45114SUPPL2016-08-23
25102SUPPL2016-07-28
34759SUPPL2016-02-23
25101SUPPL2016-02-17
12676SUPPL2015-11-25
25100SUPPL2015-11-23
34758SUPPL2015-02-17
25099SUPPL2015-02-03
20698SUPPL2008-02-19
2657SUPPL2005-03-03
20697SUPPL1998-06-08